These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

627 related items for PubMed ID: 31087185

  • 1. Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation.
    Jiang Y, Tang H, Ma X, Cheng Q, Lin H, Jin X, Zhang Z, Yu W, He S, Kobayashi T, Uehara S, Matsumoto T, Xia W.
    J Bone Miner Metab; 2019 Nov; 37(6):1036-1047. PubMed ID: 31087185
    [Abstract] [Full Text] [Related]

  • 2. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
    Matsumoto T, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, Hirakawa A, Soen S.
    J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
    [Abstract] [Full Text] [Related]

  • 3. Relationship between the effect of eldecalcitol and serum 25(OH)D level.
    Takano T, Kondo S, Saito H, Matsumoto T, Eldecalcitol Study Group.
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():124-7. PubMed ID: 24240066
    [Abstract] [Full Text] [Related]

  • 4. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study.
    Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T.
    Bone; 2011 Oct; 49(4):605-12. PubMed ID: 21784190
    [Abstract] [Full Text] [Related]

  • 5. Eldecalcitol: a review of its use in the treatment of osteoporosis.
    Sanford M, McCormack PL.
    Drugs; 2011 Sep 10; 71(13):1755-70. PubMed ID: 21902297
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
    Iba K, Sonoda T, Takada J, Dohke T, Yamashita T.
    J Bone Miner Metab; 2017 Mar 10; 35(2):171-176. PubMed ID: 26832388
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
    Mawatari T, Muraoka R, Iwamoto Y.
    Osteoporos Int; 2017 Apr 10; 28(4):1279-1286. PubMed ID: 27900428
    [Abstract] [Full Text] [Related]

  • 12. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis.
    Nuti R, Bianchi G, Brandi ML, Caudarella R, D'Erasmo E, Fiore C, Isaia GC, Luisetto G, Muratore M, Oriente P, Ortolani S.
    Rheumatol Int; 2006 Mar 10; 26(5):445-53. PubMed ID: 16283320
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and safety of vitamin D in relation to bone health.
    Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.
    Evid Rep Technol Assess (Full Rep); 2007 Aug 10; (158):1-235. PubMed ID: 18088161
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.
    Gorai I, Hattori S, Tanaka Y, Iwaoki Y.
    J Bone Miner Metab; 2012 May 10; 30(3):349-58. PubMed ID: 22130786
    [Abstract] [Full Text] [Related]

  • 16. Role of vitamin D levels and vitamin D supplementation on bone mineral density in Klinefelter syndrome.
    Ferlin A, Selice R, Di Mambro A, Ghezzi M, Di Nisio A, Caretta N, Foresta C.
    Osteoporos Int; 2015 Aug 10; 26(8):2193-202. PubMed ID: 25963234
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
    Gifre L, Vidal J, Carrasco JL, Muxi A, Portell E, Monegal A, Guañabens N, Peris P.
    Osteoporos Int; 2016 Jan 10; 27(1):405-10. PubMed ID: 26423406
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of calcium plus vitamin D supplementation during pregnancy in Brazilian adolescent mothers: a randomized, placebo-controlled trial.
    Diogenes ME, Bezerra FF, Rezende EP, Taveira MF, Pinhal I, Donangelo CM.
    Am J Clin Nutr; 2013 Jul 10; 98(1):82-91. PubMed ID: 23719547
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.